Rashmae Chardavoyne, MD
Surgery · Bellerose, NYNPI 1467556746
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 38 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 11 manufacturers, the largest accounting for just 23.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2020 at $237 and has fallen 71.8% since, to $67 in 2025. That places this record below the midpoint for surgery clinicians in NY, where the typical reported total is $1,254.
Across 38 payments — averaging $20.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Puma Biotechnology, Inc.$189
- Incyte Corporation$160
- AstraZeneca$116
- Davol Inc.$99
- Johnson & Johnson$41
- Bayer$40
- plus $152 from 5 others
What the payments were for
- Food & beverage$797100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Puma Biotechnology, Inc. | 11 | $189 |
| Incyte Corporation | 8 | $160 |
| AstraZeneca(2 entities) | 6 | $116 |
| Davol Inc. | 2 | $99 |
| Johnson & Johnson(2 entities) | 2 | $41 |
| Bayer | 2 | $40 |
| Daiichi Sankyo Inc. | 2 | $38 |
| Eisai Inc. | 2 | $35 |
| Merck | 1 | $28 |
| Pfizer | 1 | $27 |
| Novo Nordisk | 1 | $24 |
How this compares
$797 in reported general payments places this provider in the 40th percentile of 1,596 surgery providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 22 | $123 |
| Ciprofloxacin Hcl | 13 | $112 |
| Oxycodone Hcl | 14 | $23 |
Paid to pharmacies, not to this prescriber.
Other surgery in Bellerose
- Cheguevara AfanehNew York$1.4M
- Flavio Malcher Martins de OliveiraNew York$695K
- Yuri NovitskyNew York$548K
- Rasa ZarnegarNew York$478K
- Tanuja DamaniNew York$459K
- Benjamin SadowitzSyracuse$419K
- Stephen GoldstoneNy$386K
- Rache SimmonsNew York$371K
- George DenotoManhasset$333K
- Marina KurianNew York$328K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.